Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2022
>
Sanofi, GSK post 58% efficacy in omicron-affected COVID-19 vaccine trial, teeing up race to regulators
Sanofi, GSK post 58% efficacy in omicron-affected COVID-19 vaccine trial, teeing up race to regulators
Read also
Celea Therapeutics Secures $180M for Phase 3 IPF Clinical Trials Test
Celea Therapeutics secured $180 million for the Phase 3 SURPASS-IPF trial of deupirfenidone, a promising new treatment for idiopathic pulmonary fibrosis.
WHO Begins Clinical Trials For New Ebola Virus Treatments in DR Congo.
The WHO has launched clinical trials in DR Congo to evaluate MBP134 and remdesivir as potential treatments for the deadly Bundibugyo Ebola virus strain.
New Remote Blood Cancer Clinical Trials Launched for Guernsey Patients
Guernsey blood cancer patients can now join UK clinical trials remotely. A new initiative transports excess tissue and blood samples to advance cancer research.
Targeted Cancer Therapies: Ryvu Therapeutics Expands Oncology Pipeline
Polish biotech Ryvu Therapeutics advances its small-molecule targeted cancer therapies pipeline, targeting solid tumors and malignancies in clinical trials.
